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OBJECTIVES: To compare Computed Tomographic (CT) utilization and poten-
tially related cancer risks in the United States and in Canada. METHODS: While 
CT scans can provide great medical benefits, there is growing concern about 
potential cancer risks because they deliver much higher radiation doses than do 
conventional diagnostic x-rays. Using epidemiological databases, we developed a 
risk projection model to assess radiation exposure from CT use, to estimate the 
number of CT related incident cancers, according to age, gender, and CT scan 
type in Canada. 95% uncertainty limits (UL) using Monte Carlo simulations were 
estimated. These results were compared to projected cancer risks from CT scans 
performed in the United States. RESULTS: In 2007, there were 240,000 and 
114,000 CT examinations per million population in the United States and 
Canada, respectively. Scans of the abdomen/pelvis, brain, and thorax accounted 
for 88% and 78% of all CT scans in Canada and the United States. We estimated 
46 (95% UL 24 - 89) potential CT-related incident cancers per million in Canada, 
compared to 98 (51 - 152) in the United States. In the United States, 48% of 
potential cancers might be attributed to abdomen/pelvis CT scans, while in 
Canada the estimate is 66%. In Canada, 36 (18 - 71) and 56 (29 - 106) potential 
cancers per million were estimated for males and females, respectively. In the 
United States, the estimates were 76 (41 -110) and 119 (60 - 185) per million for 
males and females, respectively. CONCLUSIONS: Given the different patterns of 
care in the United States and in Canada, our findings might have important 
health policy implications. Strategies to monitor the appropriate use of CT scans, 
especially CT abdomen/pelvis, should be followed. Efforts to reduce cancer risk 
might include decreasing the number of decisionally marginal CT scans, as well 
as the dose per scan.  
 
PCN129  
ESTIMATING THE COST FOR PROSTATE CANCER (PCA) SCREENING USING THE 
PROSTATE, LUNG, COLORECTAL AND OVARIAN CANCER SCREENING TRIAL 
DATA  
Crawford D1, Qureshi Z2, Mittmann N3, Kattan M4, Dickson M5, Andriole GL6, Reding D7, 
Bennett C8 
1University of Colorado Health Sciences Center (UCHSC) in Denver, Columbia, SC, USA, 2Arnold 
School of Public Health, University of South Carolina, Columbia, SC, USA, 3Sunnybrook Health 
Sciences Centre, Toronto, ON, Canada, 4Cleveland Clinic, Columbia, SC, USA, 5Presbyterian 
College School of Pharmacy, Clinton, SC, USA, 6Washington University School of Medicine in St. 
Louis, St. Louis, MO, USA, 7Marshfield Center, Columbia, SC, USA, 8University of South Carolina, 
Columbia, SC, USA  
OBJECTIVES: To assess the impact of not screening for prostate cancer among a 
hypothetical population of men >55 years of age. METHODS: Sample included 
PLCO Screening Trial intervention participants without cancer at T0 (n=33,709) 
through 2011. Inclusion criteria: age ≥55 years, and adequate PSA or DRE exam at 
entry. Cancer was considered clinically significant if patient had confirmed PCa 
with Gleason score ≥7. Estimated PCa expenditures were based on Medicare 
costs. Results were projected to SEER incident population (n=202,500 with 
localized cancer). RESULTS: Among 2,580 PLCO men identified and treated for 
PCa after T0, estimated total expenditures were: $61.5 million, with $23,804 per 
treated patient. Among 377 PLCO men with clinically significant cancers who 
received treatment, estimated total expenditures were $8.6 million (mean, 
$22,742 per patient). Among 549 PLCO men with clinically non-significant PCa 
identified and treated after T0, estimated total expenditures were $13.6 million 
($24,831 per case). Extrapolated nationally to 96,000 clinically significant PCas 
annually, annual initial diagnosis/ treatment costs would be $2.4 billion. 
Adopting draft USPHSTF recommendations would result in $2.4 billion in initial 
savings ($23,804/patient). Many of these men will subsequently present with 
clinically significant PCa, will require systemic therapy, and will die from PCa, 
with total costs far exceeding $2.4 billion. CONCLUSIONS: The 2011 USPHSTF 
Task Force draft policy currently grades PCa screening as “(D)- do not discuss 
with patients.” A more rational policy would be to screen appropriate men for 
PCa and to treat early clinically significant PCa with surgery or radiation.  
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OBJECTIVES: We sought to describe the new molecular entities (NMEs) and new 
therapeutic biologic applications (BLAs) approved by the US Food and Drug 
Administration (FDA) in the period 1980-2012, and to assess differences in drug 
approvals and discontinuations between oncology products and products from 
other therapeutic classes. METHODS: Drug approval data were collected from 
FDA databases publicly available on its website, and the FDA Approved Drug 
Products with Therapeutic Equivalence Evaluations (1980-2012). The unit of 
analysis was the pharmaceutical active ingredient or combination of ingredients 
approved by the FDA. Data were updated to December 31, 2012. Descriptive 
analysis and the chi-square test were used in the analysis. RESULTS: The FDA 
listed 2,479 approved active ingredients or combinations of active ingredients in 
the period 1980-2012; including 99 BLAs and 2,380 NMEs. Oncology products 
represented 5.3% (n=126) of NMEs and 43.4% (n=43) of BLAs. The FDA listed 34 
oncology products approved before 1980, 12 in the 1980s, 49 in the 1990s, 51 in 
the 2000s, and 23 in 2010-2012. The oncology products (0.6%) and other products 
(23.8%) were approved as a fixed-dose combination (p<0.001). In January 1, 1980 
the FDA listed 949 products of which 33 (3.5%) were oncology products. In the 
period 1980-2012, the FDA approved 1,530 products, including 136 oncology 
products (8.9%). In December 31, 2013, 92.9% of all the approved oncology 
products and 68.7% of other products were listed as marketed by the FDA 
(p<0.001). CONCLUSIONS: Oncology drugs experienced a rapid increase in 
approvals in the past 2 decades while the approvals in other therapeutic classes 
declined significantly. Biologics represented a larger proportion of the approvals 
of oncology products than products from other therapeutic classes. 
Pharmaceutical companies continue to invest in R&D in oncology and other 
niche markets without adequate therapeutic alternatives.  
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OBJECTIVES: Lung cancer is the most frequent cause of cancer death with 
cigarette smoking being the number one risk factor. Nearly 90% of lung cancer 
deaths are attributable to smoking. Smoking in patients diagnosed with lung 
cancer decreases the rate of survival, quality of life, and reduces the 
effectiveness of medical treatment in these patients. One of the ways to stop 
smoking is through the use of smoking cessation agents. The purpose of this 
study is to explore the prevalence of smoking among lung cancer patients and 
patient reported use of smoking cessation agents using a national dataset. 
METHODS: A retrospective study was done to identify lung cancer patients (ICD-
9 = 162) who smoke and those who use smoking cessation agents from 2006-2010 
using Medical Expenditure Panel Survey (MEPS) data. Number of patients who 
smoke and those who use smoking cessation agents were described. RESULTS: 
Data from five years identified nearly 260 lung cancer patients. Out of these, 48 
patients, accounting for 18.4% prevalence, reported smoking even after 
diagnosed with lung cancer. Percentage of female smokers was 58.33% while that 
of males was 41.66%. Medication history for these patients revealed a very low 
proportion, (i.e. 6/48 or 12.5%) reported using any form of smoking cessation 
agents. CONCLUSIONS: It is evident from the results that significant numbers of 
patients continue smoking even after diagnosis. This might be an 
underestimated number as this was patient reported information. There may be 
more patients that have not reported smoking because of social dogma. This 
shows that the non-medical efforts to quit smoking might have been 
unsuccessful. Also, the use of smoking cessation agents among these patients is 
extremely low. This is an alarming matter and future research should focus on 
identifying barriers to use of smoking cessation agents and approaches to 
address those barriers.  
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OBJECTIVES: Bevacizumab (Bev, Avastin®), the first FDA-approved anti-
angiogenesis agent, has been used as adjuvant therapy for the treatment of 
metastatic colorectal cancer (mCRC) since 2004. This study aimed to evaluate the 
utilization of Bev among elderly mCRC patients aged 65 and older within the US. 
METHODS: This retrospective cohort study used the SEER-Medicare data. Our 
cohort included individuals aged 65 years or older who were incident CRC 
patients diagnosed in 2005-2007 and received chemotherapy at any time through 
December 2009 (date of first chemotherapy = index date). This included patients 
with newly diagnosed metastatic disease, as well as CRC patients who 
progressed from initially diagnosed localized/regional disease (recurrence). We 
ascertained comorbid conditions using ICD-9 codes from inpatient, outpatient, 
and physician claims within one year prior to the index date. Logistic regression 
adjusted for patient characteristics was conducted to assess the likelihood of Bev 
use. RESULTS: A total of 6,804 patients were identified. The mean age at index 
date was 74 years and 50.3% were male. There were 2,792 (41.0%) patients 
received Bev, among which the average number of Bev cycles was 11.9 
(median=9). Bev was used in 64% of patients with metastatic CRC and 26% of 
patient with recurrent disease. After adjustment for all other variables, we found 
that patients were less likely to receive Bev if they were with age>=80 compared 
with those aged 65-69 (adjusted odds ratio [OR] = 0.81 [95% CI: 0.69-0.94]; p<0.01), 
or had evidence of arterial thromboembolism (OR = 0.70 [0.54-0.90; p<0.0001) 
prior to chemo initiation. We also observed a trend of increasing Bev use over 
calendar time as well as substantial geographic variation in its use. 
CONCLUSIONS: Less than half of Bev-indicated patients received Bev in US 
Medicare population. Patients’ age and history of arterial thromboembolism 
significantly contribute to the low utilization of Bev.  
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OBJECTIVES: To analyzed the pattern and factors associate with the utilization 
of Traditional Chinese Herbal Medicine (TCHM) in Traditional Chinese Medicine 
(TCM) hospitals in China. METHODS: We examined 87,248 inpatient records in 
100 TCM hospitals from 2003 to 2007. Use of TCHM are analysed by a logit model. 
Major factors associate with the utilization includes patients’ and hospitals’ 
characteristics. RESULTS: TCHM use is positively related to a patient’s age. 
Female, ethnic group, health insurance status, and disease types also associate 
with TCHM utilization. Patients in critical conditions (OR=1.27, P<0.01) are more 
likely to use TCHM than those in stable conditions. However, patients admitted 
from emergency department are less likely to use TCHM (OR=0.75, P<0.01). 
